| Revenue growth | ₹4,670.81 lakh (+89.59% YoY) in FY26. |
|---|---|
| Margins | EBITDA margin at 16.06% in FY26 vs 19.31% in FY25. |
| Demand visibility | Strong; 50k+ prescriptions per day and 10k+ doctors. |
| Management confidence | High; aiming for global footprint by 2030. |
Growth
FY26 Revenue reached ₹4,670.81 lakh (+89.59% YoY); EBITDA at ₹750.32 lakh (+57.73% YoY); PAT at ₹461.99 lakh (+49.05% YoY).
Outlook
Targets 500+ products in 3 years; pan-India expansion by 2029; launching new Mindcare and Orbit divisions.
Risks
Dependence on contract manufacturers; competitive pharmaceutical market; regulatory compliance across diverse geographies.
Earnings Call filed with BSE, BSE: 544529. Summary written with AI assistance from the document.
Aptus Pharma Ltd: key numbers
- Share price
- ₹347.00
- Market cap
- ₹595.1 Cr
- Revenue (annual)
- ₹46.57 Cr
- Net profit (annual)
- ₹4.62 Cr
- P/E (TTM)
- 128.8×Sector 50.4×
- Promoter holding
- 72.89%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Aptus Pharma Ltd
All →Aptus Pharma Annual General Meeting
Aptus Pharma Ltd issued a corrigendum to its 16th AGM notice regarding inadvertent errors in the explanatory statement for item no. 3.
Aptus Pharma H2 FY26 Results: Net Profit ₹2.9 Cr, Up 61.1% YoY
Aptus Pharma Ltd reported revenue from operations of ₹32.2 Cr (+117.6% YoY) and net profit of ₹2.9 Cr (+61.1% YoY) for H2 FY26.
- Key figure
- Net profit ₹2.9 Cr · +61.1% YoY